The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial.
Cesar Augusto Santa-Maria
No relevant relationships to disclose
Aditya Bardia
No relevant relationships to disclose
Amanda Blackford
No relevant relationships to disclose
Roisin M. Connolly
Research Funding - Genentech; Novartis; Puma
John H. Fetting
No relevant relationships to disclose
Stacie Jeter
No relevant relationships to disclose
Robert Stephen Miller
No relevant relationships to disclose
Anne T Nguyen
No relevant relationships to disclose
Katie Quinlan
No relevant relationships to disclose
Shannon Slater
No relevant relationships to disclose
Claire Frances Snyder
Stock Ownership - Express Scripts; Immunomedics; Merck; Oncolytics Biotech
Antonio C. Wolff
No relevant relationships to disclose
Jane Zorzi
No relevant relationships to disclose
N. Lynn Henry
Research Funding - AstraZeneca
Vered Stearns
Research Funding - Novartis; Pfizer